{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "exchangeTimezoneName": "Europe/London", "exchangeTimezoneShortName": "BST", "currency": "EUR", "market": "gb_market", "esgPopulated": false, "gmtOffSetMilliseconds": 3600000, "exchange": "CXE", "longName": "MedinCell S.A.", "shortName": "Medincell SA", "regularMarketPrice": 9.36, "regularMarketChangePercent": 0.0, "marketState": "CLOSED", "fiftyTwoWeekHighChangePercent": -0.025000075, "fiftyTwoWeekLow": 8.65, "fiftyTwoWeekHigh": 9.6, "earningsTimestamp": 1686653940, "earningsTimestampStart": 1686653940, "earningsTimestampEnd": 1686653940, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "fiftyTwoWeekLowChange": 0.71000004, "fiftyTwoWeekLowChangePercent": 0.08208093, "fiftyTwoWeekRange": "8.65 - 9.6", "fiftyTwoWeekHighChange": -0.24000072, "epsTrailingTwelveMonths": -1.08, "sharesOutstanding": 0, "bookValue": -1.039, "fiftyDayAverage": 8.977693, "fiftyDayAverageChange": 0.38230705, "fiftyDayAverageChangePercent": 0.04258411, "twoHundredDayAverage": 8.977693, "twoHundredDayAverageChange": 0.38230705, "twoHundredDayAverageChangePercent": 0.04258411, "marketCap": 210805920, "priceToBook": -9.008661, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1682319600000, "priceHint": 2, "regularMarketChange": 0.0, "regularMarketTime": 1683122283, "regularMarketDayHigh": 9.36, "regularMarketDayRange": "9.36 - 9.36", "regularMarketDayLow": 9.36, "regularMarketVolume": 3321, "regularMarketPreviousClose": 9.36, "bid": 7.25, "ask": 8.08, "fullExchangeName": "Cboe UK", "financialCurrency": "EUR", "regularMarketOpen": 9.6, "averageDailyVolume3Month": 255, "averageDailyVolume10Day": 332, "symbol": "MEDCLP.XC"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "3 rue des FrEres LumiEre", "city": "Jacou", "zip": "34830", "country": "France", "phone": "33 4 67 02 13 67", "website": "https://www.medincell.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "MedinCell S.A. develops various therapeutic solutions in France. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. The company's products in development include mdc-IRM, a risperidone extended-release injectable suspension completed Phase III trial for use in the treatment of schizophrenia; mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain & inflammation; and mdc-TJK, a subcutaneous injection in Phase III trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials, such as mdc-ANG, an antipsychotic product for use in the treatment of schizophrenia; mdc-TTG for Covid-19 and its variants; mdc-GRT for use in organ transplant; mdc-WWM for contraception; mdc-STM for use in malaria; mdc-KPT for use in acute pain for pets; and mdc-IRM for use in neuroscience. The company was incorporated in 2003 and is based in Jacou, France.", "fullTimeEmployees": 151, "companyOfficers": [{"maxAge": 1, "name": "Mr. Christophe  Douat", "age": 56, "title": "CEO & Chairman of Exec. Board", "yearBorn": 1966, "fiscalYear": 2022, "totalPay": {"raw": 290662, "fmt": "290.66k", "longFmt": "290,662"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jaime  Arango", "title": "CFO & Member of Exec. Board", "fiscalYear": 2022, "totalPay": {"raw": 183698, "fmt": "183.7k", "longFmt": "183,698"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Joel  Richard", "title": "Member of Exec. Board", "fiscalYear": 2022, "totalPay": {"raw": 217400, "fmt": "217.4k", "longFmt": "217,400"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Franck  Pouzache", "title": "Chief People Officer", "fiscalYear": 2022, "totalPay": {"raw": 151578, "fmt": "151.58k", "longFmt": "151,578"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. David  Heuze", "title": "Head of Communication & IR and Member of Exec. Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Adolfo  Lopez-Noriega", "title": "Head of R&D and Member of Exec. Board", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Julie  Alimi", "title": "Head of Legal", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Sebastien  Enault", "title": "Chief Bus. Officer", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Helen  Martin", "title": "Head of Alliance & Project Management", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Quiterie De Beauregard", "title": "Head of Portfolio", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 10, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 9, "overallRisk": 8, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}